Article

Botulinum cosmetic injectors to cure blindness in Africa

Richard Weiss, MD, a Botox cosmetic injector, will bring physicians from all over the country for a fundraiser on November 16, 2007. The profits will be donated to curing blindness in Africa through the Eyes of Africa Initiative of the One World Sight Project. Despite the ease and affordability of the cataract treatment available to Africans, cataract is still responsible for almost half of the 7 million blind Africans.

Richard Weiss, MD, a botulinum (Botox, Allergan) cosmetic injector, will bring physicians from all over the country for a fundraiser on Nov. 16, 2007. The profits will be donated to curing blindness in Africa through the Eyes of Africa Initiative of the One World Sight Project. Despite the ease and affordability of the cataract treatment available to Africans, cataracts are still responsible for almost half of the 7 million blind Africans.

Due to the success of a pilot project in 2005, when 49 patients were treated in one day, which raised funds that cured 132 people of blindness in Tanzania and Tibet, the goal is to expand on this effort. Previously held only in southern California, this year's event will span the entire United States, with more than $175,000 already raised from more than 45 physicians around the country.

The makers of Botox (Allergen Medical, a division of Allergan Inc.) will once again donate the product and doctors will be donating their time.

Completion of the first comprehensive training center for community ophthalmology in Africa, to be located in Moshi, Tanzania, will be supported by the current Eyes of Africa initiative. There will also be a relief component with the training center, performing hundreds of live cataract surgeries simultaneous with the fundraising.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.